StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO - Free Report) from a sell rating to a hold rating in a research report sent to investors on Monday morning.
A number of other equities research analysts have also recently issued reports on ABEO. HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Monday. Oppenheimer started coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They set an "outperform" rating and a $16.00 price target on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.50.
Check Out Our Latest Report on ABEO
Abeona Therapeutics Stock Down 1.3 %
Shares of ABEO stock traded down $0.07 on Monday, hitting $4.98. The company's stock had a trading volume of 347,179 shares, compared to its average volume of 337,142. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The stock has a market capitalization of $216.27 million, a price-to-earnings ratio of -1.85 and a beta of 1.79. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $8.45. The firm's fifty day moving average price is $5.42 and its 200-day moving average price is $5.81.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.19. Research analysts anticipate that Abeona Therapeutics will post -1.16 EPS for the current year.
Hedge Funds Weigh In On Abeona Therapeutics
Several institutional investors have recently modified their holdings of the business. Twinbeech Capital LP acquired a new position in shares of Abeona Therapeutics during the 4th quarter worth approximately $58,000. Squarepoint Ops LLC acquired a new position in shares of Abeona Therapeutics during the 4th quarter worth about $67,000. Jane Street Group LLC bought a new stake in shares of Abeona Therapeutics in the 3rd quarter valued at about $84,000. Oxford Asset Management LLP acquired a new stake in Abeona Therapeutics in the 4th quarter valued at about $118,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Abeona Therapeutics during the third quarter worth about $151,000. Institutional investors own 80.56% of the company's stock.
Abeona Therapeutics Company Profile
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Read More
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
